Clinical Trials Using Ulixertinib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Ulixertinib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-6 of 6
  • Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
    Location: 1189 locations

  • Ulixertinib in Treating Patients with Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

    This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a genetic alteration (mutation) in a signaling pathway called MAPK. A signaling pathway consists of a group of molecules in a cell that control one or more cell functions. Genes in the MAPK pathway are frequently mutated in many types of cancers. Ulixertinib may stop the growth of cancer cells that have mutations in the MAPK pathway.
    Location: 89 locations

  • Ulixertinib with Nab-Paclitaxel and Gemcitabine Hydrochloride in Treating Patients with Metastatic Pancreatic Cancer

    This phase Ib trial studies the side effects of ulixertinib with nab-paclitaxel and gemcitabine hydrochloride in treating patients with pancreatic cancer that has spread to other places in the body. Ulixertinib and gemcitabine hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ulixertinib and gemcitabine hydrochloride together with nab-paclitaxel may kill more tumor cells.
    Location: 2 locations

  • Ulixertinib and Palbociclib in Treating Patients with Advanced or Refractory Solid Tumors or Metastatic Pancreatic Cancer

    This phase I trial studies the side effects and best dose of ulixertinib and palbociclib and to see how well they work in treating patients with solid tumors that have spread to other places in the body or do not respond to treatment or pancreatic cancer that has spread to other places in the body. Ulixertinib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Ulixertinib in Treating Patients with Stage IV Uveal Melanoma

    This phase II trial studies the side effects of ulixertinib and how well it works in treating patients with stage IV uveal melanoma. Ulixertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: See Clinical Trials.gov

  • Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

    This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and / or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
    Location: 142 locations